It remains necessary to formally eliminate an infectious granulomatous disease or a demyelinating inflammatory pathology before initiating anti‐TNFα treatment (TNF neutralization in MS: results of a randomized, placebo‐controlled multicenter study, 1999). The gene discussed is TNF; the disease is myeloid sarcoma.